Sanofi abandoned the development of mRNA COVID-19 vaccine
- Why are vegetarians more likely to suffer from depression than meat eaters?
- Small wireless device implanted between skin and skull helps kill cancer cells
- Will the mRNA vaccine that can cure cancer come out near soon?
- Allogeneic T-cell therapy set for landmark first approval
- Boston University denies that the new COVID strain they made has 80% fatality rate
- A new generation of virus-free CAR-T cell therapy
Sanofi abandoned the development of mRNA COVID-19 vaccine
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- New breakthrough in CAR-T cell therapy: Lupus erythematosus patients achieved treatment-free remission for up to 17 months
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
- Where do the bacteria in the human gut come from?
Sanofi abandoned the development of mRNA COVID-19 vaccine, will explore modified mRNA technology.
Based on unmodified mRNA technology, there may be technical lag in the next COVID-19 vaccine research and development.
Sanofi’s “timely stop loss” has also received positive feedback from the market. For the COVID-19 vaccine market currently in the “Red Sea”, the true ceiling may be that the pandemic era is about to pass.
Sanofi’s US$3.2 billion acquisition of TranslBio is still in ink, and the large French pharmaceutical company is already adjusting its research and development plan. Sanofi abandoned the development of the mRNA COVID-19 vaccine based on the interim data of the phase 1/2 clinical trial, and will focus on the development of the mRNA influenza vaccine in the future.
First of all, Sanofi believes that the mid-term clinical results are positive, but believes that it is of no value to launch the mRNA COVID-19 vaccine on the market long after Pfizer and Moderna. Two weeks after receiving the second dose of the vaccine, 91% to 100% of the participants in the three doses had a four-fold or more increase in neutralizing antibody levels from baseline. Sanofi said that there are no safety issues and the tolerance is “equal” to other unmodified mRNA vaccines.
Among them, Pfizer/BioNTech and Moderna developed chemically modified mRNA technologies to try to bypass the inflammatory response to foreign nucleic acids, while CureVac and TranslBio’s unmodified mRNA technologies evade detection by the immune system by relying on changes in RNA sequences.
The great success of Pfizer/BioNTech and Moderna vaccines is in sharp contrast with CureVac’s clinical data. Although the variant cycle in the CureVac clinical trial may partially explain the different efficacy results, with the research also supporting the situation, researchers have seen that modification of mRNA is a critically successful way.
Sanofi seems to have joined the queue of supporters of modified mRNA. Translate Bio, acquired by Sanofi for US$3.2 billion, focuses on unmodified mRNA and the Shire research team behind its platform. In July of this year, Thomas Triomphe, head of Sanofi Pasteur, told investors that the company will explore unmodified and modified mRNA to obtain the best constructs.
However, modified mRNA is now the focus of Sanofi. In a statement disclosing Phase 1/2 clinical data, Sanofi stated that it is “accelerating the conversion of the platform into modified mRNA.”
Sanofi’s goal next year is to clinically launch a modified quadrivalent influenza mRNA vaccine. Sanofi and Translate Bio became the first companies to start testing seasonal mRNA influenza vaccine candidates in June, but their attention has turned to their modified quadrivalent vaccines. This week, Pfizer began a phase 1 clinical trial of a quadrivalent mRNA vaccine against influenza.
In addition, Sanofi and the United Kingdom GlaxoSmithKline (GSK.US) co-developed recombinant protein COVID-19 vaccine (including adjuvant) Phase III clinical trial results are expected to be announced before the end of this year.
Sanofi abandoned the development of mRNA COVID-19 vaccine
(source:internet, reference only)
Disclaimer of medicaltrend.org
